|
Gleason 7 (3+4)
n/N (%)
|
Gleason 7 (4+3)
n/N (%)
|
p value |
Preoperative serum PSA |
|
|
|
≤ 4,00ng/ml |
0 |
0 |
0.06
|
> 4,00 and ≤ 9,99ng/ml |
5/7 (71) |
2/7 (29) |
> 9,99ng/ml |
2/7 (29) |
5/7 (71) |
Percentage of gland involvement by carcinoma |
|
|
|
≤ 10% |
2/11 (18) |
0 |
0.03
|
> 10% and ≤ 20% |
5/11 (46) |
2/9 (22) |
> 20% and ≤ 30% |
2/11 (18) |
3/9 (33) |
> 30% and ≤ 40% |
2/11 (18) |
3/9 (33) |
> 60% and ≤ 80% |
0 |
1/9 (11) |
Positive circumferential surgical margin |
4/11 (36) |
4/9 (44) |
1.00 |
Positive basal surgical margin |
0 |
4/9 (44) |
0.03 |
Positive apical surgical margin |
3/11 (27) |
0 |
0.22 |
Extraprostatic extension |
2/11 (18) |
5/9 (56) |
0.15 |
Seminal vesicle invasion |
1/11 (9) |
4/9 (44) |
0.12 |
Ki-67 immunostaining (% of cancer cells) |
|
|
|
Negative |
2/11 (18) |
0 |
0.04
|
> 0% and ≤ 3,0% |
9/11(82) |
7/9 (78) |
> 3,0% |
|
2/9 (22) |